Viral Bioterrorism and Antiviral Countermeasures

Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats

Volumn , Issue , 2005, Pages 16-28

  Bray, Mike ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Bioterrorism; Biowarfare; Host response; Smallpox; Variola virus; Viral hemorrhagic fever

Indexed keywords

EID: 84891013681     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471716715.ch2     Document Type: Chapter

References (38)

1. Henderson, D. A. The looming threat of bioterrorism. Science 1999, 283, 1279-1282.
2. Monto, A. The role of antivirals in the control of influenza. Vaccine 2003, 21, 1796-1800.
3. Bray, M; Roy, C. J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 2004, 54, 1-5.
4. www.niaid.nih.gov/biodefense.
5. Eitzen, E. M. Use of biological weapons. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 437-450.
6. Eitzen, E. M.; Takafuji, E. Historical overview of biological warfare. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 415-436.
7. Rotz, L.; Khan, A.; Lillibridge, S. R.; Ostroff, S. M.; Hughes, J. M. Public health assessment of potential biological terrorism agents. Emerging Infect. Dis. 2002, 8, 225-229.
8. Henderson, D; Inglesby, T.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Jahrling, P. B.; Hauer, J.; Layton, M; McDade, J.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T.; Russell, P. K.; Tonat, K. Smallpox as a biological weapon: medical and public health management. JAMA 1999, 281, 2127-2137.
9. Jahrling, P. B. Viral hemorrhagic fevers. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 591-602.
10. Borio, L.; Inglesby, T.; Peters, C. J.; Schmaljohn, A. L.; Hughes, J. M.; Jahrling, P. B.; Ksiazek, T.; Johnson, K. M.; Meyerhoff, A.; O'Toole, T.; Ascher, M. S.; Bartlett, J.; Breman, J. G.; Eitzen, E. M. Jr.; Hamburg, M.; Hauer, J.; Henderson, D. A.; Johnson, R. T.; Kwik, G.; Layton, M.; Lillibridge, S.; Nabel, G. J.; Osterholm, M. T.; Perl, T. M.; Russell, P.; Tonat, K.; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons-medical and public health management. JAMA 2002, 287, 2391-2405.
11. Franz, D.; Jahrling, P. B; McClain, D. J.; Hoover, D. L.; Byrne, W. R.; Pavlin, J. A.; Christopher, G. W.; Cieslak, T. J.; Friedlander, A. M.; Eitzen, E. M. Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278, 399-411.
12. Smith, J.; Davis, K. Viral encephalitides. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 561-589.
13. Alibek, J.; Handelman, S. Biohazard. Random House, New York, 1999.
14. Bray, M.; Buller, R. M. L. Looking back at smallpox. Clin. Infect. Dis. 2004, 38, 882-890.
15. Basler, C. F.; Wang, X.; Muhlberger, E.; Volchkov, V.; Paragas, J.; Klenk, H. D.; Garcia-Sastre, A.; Palese, P. The Ebola virus VP35 protein functions as a type IIFN antagonist. Proc. Natl. Acad. Sci. USA 2000, 97, 12289-12294.
16. Basler, C. F.; Mikulasova, A.; Martinez-Sobrido, L.; Paragas, J.; Muhlberger, E.; Bray, M.; Klenk, H. D.; Palese, P.; Garcia-Sastre, A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77, 7945-7956.
17. Bray, M.; Mahanty, S. Ebola hemorrhagic fever and septic shock. J. Infect. Dis. 2003, 188, 1613-1617.
18. Geisbert, T. W.; Hensley, L. E.; Larsen, T.; Young, H. A.; Reed, D. S.; Geisbert, J. B.; Scott, D. P.; Kagan, E.; Jahrling, P. B.; Davis, K. J. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques. Am. J. Pathol. 2003, 163, 2347-2370.
19. Mahanty, S.; Bray, M. Pathogenesis of filoviral hemorrhagic fevers. Lancet Infect. Dis. 2004, 4, 487-498.
20. Geisbert, T. W.; Young, H. A.; Jahrling, P. B.; Davis, K. J.; Kagan. E.; Hensley, E. Mechanism underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages. J. Infect. Dis. 2003, 188, 1618-1629.
21. Van Dissel, J. T.; van Langevelde, P.; Westendorp, R. G.; Kwappenberg, K.; Frolich, M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998, 351, 950-953.
22. Hill, A. V. The genomics and genetics of human infectious disease susceptibility. Annu. Rev. Genomics Hum. Genet. 2001, 2, 373-400.
23. Westendorp, R. G.; Langermans, J. A.; Huizinga, T. W.; Verweij, C. L.; Sturk, A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997, 349, 1912-1917.
24. Baize, S.; Leroy, E. M; Georges, A. J.; Georges-Courbot, M. C.; Capron, M.; Bedjabaga, I.; Lansoud-Soukate, J.; Mavoungou, E. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 2002, 128, 163-168.
25. Dowell, S. F.; Mukunu, R.; Ksiazek, T. G.; Khan, A. S.; Rollin, P. E.; Peters, C. J. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit J. Infect. Dis. 1999, 179 Suppl 1, S87-91.
26. Bray, M. Filoviridae. In Clinical Virology, 2nd Ed., Richman, D. R.; Whitley, R. J.; Hayden, F. G. (eds.), ASM Press, Washington, DC, 2002, pp. 875-890.
27. Bray, M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57, 53-60.
28. Anonymous. Infection control for viral hemorrhagic fevers in the African health care setting. Centers for Disease Control and Prevention, Atlanta, 1998.
29. Baker, R. O.; Bray, M.; Huggins, J. W. Potential antiviral therapeutics for smallpox and other orthopoxvirus infections. Antiviral Res. 2003, 57, 13-23.
30. Neyts, J.; De Clercq, E. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res. 2003, 57, 25-33.
31. Bray, M.; Kefauver, D.; Martinez, M.; West, M.; Roy, C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 2002, 54, 129-142.
32. Roy, C.; Baker, R.; Washburn, K.; Bray, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob. Agents Chemother. 2003, 47, 2933-2937.
33. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J. R.; Hostetler, K. Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991-995.
34. Ciesla, S.; Trahan, J.; Wan, W. B.; Beadle, J. R.; Aldern, K. A.; Painter, G. R.; Hostetler, K. Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003, 59, 163-171.
35. Bray. M; Martinez, M.; Smee, D.; Kefauver, D.; Thompson, E.; Huggins, J. W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus infection. J. Infect. Dis. 2000, 181, 10-19.
36. Andrei, G.; De Clercq, E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993, 22, 45-75.
37. Bray, M.; Paragas, J. Experimental therapy of filovirus infections. Antiviral Res. 2002, 54, 1-17.
38. Geisbert, T. W.; Hensley, L. E.; Jahrling, P. B.; Larsen, T.; Geisbert, J. B.; Paragas, J.; Young, H. A.; Fredeking, T. M.; Rote, W. E.; Vlasuk, G. P. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362, 1953-1958.